ImmunityBio, Inc. (NASDAQ: IBRX) shares plummeted 5.09% during Tuesday's intraday trading session, following the company's release of its Full Year 2024 financial results. Despite beating earnings per share (EPS) expectations, the biotechnology firm's revenue fell short of analyst estimates, weighing on investor sentiment.
According to the report, ImmunityBio generated revenue of $14.7 million for the fiscal year 2024, up from $0.6 million in the previous year but missing analysts' forecasts by 31%. However, the company reported a narrower net loss of $413.6 million, translating to an EPS loss of $0.59, which exceeded expectations by 26%.
While ImmunityBio's revenue growth trajectory remains strong, with a projected 55% annualized increase over the next three years, investors appear to have reacted negatively to the missed revenue target. The company's shares are now down 11% from a week ago.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.